RxDoctor Payments Data

Stacey June, DO

Plastic and Reconstructive Surgery · Danbury, CTNPI 1568609121

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,981 of the $2,346 with a category attached, or 84.4%. 27 manufacturers reported payments, led by Medical Device Business Services, Inc. at 25.2% of the total. Reporting peaked in 2023 at $1,117 and has fallen 69.1% since, to $345 in 2025.

$2,346in general payments, 2019–2025

Across 93 payments — averaging $25.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$591
  • AbbVie$275
  • TELA Bio, Inc.$194
  • Endo USA, Inc.$190
  • Incyte Corporation$151
  • Musculoskeletal Transplant Foundation Inc.$144
  • plus $800 from 21 others

What the payments were for

  • Travel & lodging$34715%
  • Food & beverage$1,98184%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,346 in reported general payments places this provider in the 75th percentile of 41 plastic and reconstructive surgery providers in Connecticut.

See all plastic and reconstructive surgery providers in Connecticut

Medicare billing

Part B allowed, 2024
$123,288
Medicare patients
154
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mupirocin36$288
Cefadroxil15$108
Tramadol Hcl13$59
Levofloxacin11$40
Oxycodone Hcl13$38

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →